KR20140050943A - Composition comprising thiazolone derivative for inhibiting platelet aggregation - Google Patents

Abstract

The present invention relates to a composition for inhibiting platelet aggregation comprising a thiazolone derivative as an active ingredient. The thiazolone derivative according to the present invention has an excellent effect of inhibiting platelet aggregation induced by thrombin, and thus can be usefully used as a composition for inhibiting platelet aggregation and a composition for preventing or treating thrombotic diseases.

Description

[0001] The present invention relates to a thiazolone derivative for inhibiting platelet aggregation,

The present invention relates to a composition for inhibiting platelet aggregation comprising a thiazolone derivative as an active ingredient.

Thrombosis is an aggregation of blood factors, mainly composed of aggregates of platelets and fibrin, and is usually formed to prevent excessive bleeding of blood vessels. When the platelets come into contact with the expression of the subcutaneous layer, a thrombus is formed to initiate a reaction to block the vasculature. This process is called hemostasis, and this process is very important to prevent excessive bleeding from the wound site. Arterial thrombosis causes serious disease due to local occlusion, whereas venous thrombosis mainly causes distant occlusion, or embolization. Therefore, the medicament which inhibits platelet aggregation inhibition or thrombolytic action can be used for the treatment of diseases associated with thrombus and embolism, such as myocardial infarction, angina pectoris, thrombotic phlebitis, arterial embolism, coronary and cerebral arterial thrombosis, peripheral vascular or deep vein thrombosis, Pathologic symptoms after thromboembolism and subarachnoid haemorrhage, percutaneous coronary angioplasty (PTCA), coronary artery bypass grafting (PTCA), coronary artery bypass grafting ) And stent insertion, stent restenosis after stent placement, catheter thrombotic occlusion or reocclusion, acute coronary syndrome, TIA (transient ischemic attack or acute cerebral angiopathy syndrome), heart failure, chest due to ischemic pathology Pain syndrome, X syndrome, diabetes mellitus. There are blood coagulation and thrombus formation mechanisms in the blood vessel blocking mechanism.

The blood coagulation mechanism changes the soluble fibrinogen to an insoluble fibrin and the blood coagulates. The main initiator is the exogenous factor tissue factor (TF) and the exogenous factor VIIa factor (factor VIIa) (Pia Siljander 1-80, HELSINKI 2000). At each stage, several clotting factors are activated to form a fibrin colt (cross-linked fibrin molecule), which in turn produces thrombin, which stimulates the release of the activating factor by a strong platelet active.

The thrombus formation mechanism is a voluntary process to prevent hemorrhage from damaged blood vessels, not to normal vascular endothelial cells, since platelets adhere to collagen upon impaired vascular endothelium formation and form a viscous gelatin mass by mutual activation.

Drugs such as thrombolytic agents and antiplatelet agents are known to remove these blood clots. The thrombolytic agent is a drug that rapidly cleaves thrombus by catalyzing the formation of serine protease plasmin from plasminogen. It is a drug that can be used to treat streptokinase, urokinase, APSAC, t- PA, and the antiplatelet agents regulated by Group 3 substances are catecholamine, collagen, thrombin, prostacyclin, which is produced outside the platelets and acts on platelet membrane receptors; ADP, PGD2, PGE2, serotonin, which are produced in platelets and act on membrane receptors; And prostaglandin endoperoxide, thromboxane A2 (TXA2), cAMP, cGMP, and Ca2 +, which are produced inside the platelets and act in the platelets. The antiplatelet agent is also known as a calcium ionophore, which binds to the cell membrane to form calcium channel into the cell calcium to induce aggregation, and A23187, a thromboxane A2 analog (thromboxane A2 analog) (Tina Ritzema, The International Journal of Biochemistry & Cell Biology, 36: 1187-1205, 2004), Norimichi Nakahata, et al. Satoko Ohkubo, Emiko Ito, Toxicon, 37: 1375-1389, 1999). However, the thrombolytic agents or antiplatelet agents developed so far have problems causing various adverse effects such as hemostatic hypertrophy, infertility, and digestive disorders.

Accordingly, the inventors of the present invention conducted a study to develop a novel platelet aggregation inhibiting composition, and as a result, they confirmed that thiazolone derivative (PT1) has an excellent effect of inhibiting platelet aggregation, thereby completing the present invention.

An object of the present invention is to provide a composition for inhibiting platelet aggregation comprising a thiazolone derivative (PT1) as an active ingredient.

It is still another object of the present invention to provide a composition for preventing or treating thrombotic diseases comprising a thiazolone derivative (PT1) as an active ingredient.

In order to achieve the above object, the present invention provides a composition for inhibiting platelet aggregation comprising a thiazolone derivative (PT1) as an active ingredient.

The present invention also provides a composition for preventing or treating thrombotic diseases comprising a thiazolone derivative (PT1) as an active ingredient.

The thiazolone derivative (PT1) according to the present invention has an excellent effect of inhibiting thrombin-induced platelet aggregation, and thus can be effectively used as a composition for inhibiting platelet aggregation and a composition for preventing or treating thrombotic diseases.

1 and 2 are graphs showing platelet aggregation inhibitory effects of the thiazolone derivative (PT1) of the present invention.

Hereinafter, the present invention will be described in more detail.

The present invention provides a composition for inhibiting platelet aggregation comprising a thiazolone derivative (PT1) represented by the following general formula (1) as an active ingredient.

The present invention also provides a composition for preventing or treating thrombotic diseases, comprising a thiazolone derivative (PT1) represented by the following general formula (1) as an active ingredient.

The composition comprises a pharmaceutical composition or a food composition.

The thiazolone derivative of the above formula (1) can be obtained by reacting PT1 (2-Chloro-5 - [[5- [4,5- -oxo-2-thiazolyl] amino] benzoic acid), the molecular formula is C ₂₃ H ₁₆ ClN ₃ O ₆ S, and the molecular weight is 497.91.

The thiazolone derivative (PT1) according to the present invention has an excellent effect of inhibiting thrombin-induced platelet aggregation, and thus can be effectively used as a composition for inhibiting platelet aggregation and a composition for preventing or treating thrombotic diseases.

The thrombotic disease is selected from the group consisting of myocardial infarction, angina pectoris, thrombotic phlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, peripheral vascular thrombosis, deep vein thrombosis, arterial thrombosis, venous thrombosis, ischemic cerebral infarction, arteriosclerosis, hypertension, pulmonary hypertension, (PTCA) or stent implantation, restenosis after stent placement, catheter thrombosis, coronary artery occlusion, and / or atherosclerosis. Including, but not limited to, one or more selected from the group consisting of acute coronary syndrome, TIA (transient ischemic attack or acute cerebral vascular syndrome) and heart failure.

The composition of the present invention may further contain at least one known active ingredient having a thrombolone derivative (PT1), which has an effect of inhibiting platelet aggregation or preventing or treating thrombotic diseases.

The compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions. In addition, it can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral preparations such as syrups and aerosols, external preparations, suppositories and sterilized injection solutions according to a conventional method. Suitable formulations known in the art are preferably those as disclosed in Remington ' s Pharmaceutical Science, recently, Mack Publishing Company, Easton PA. Examples of carriers, excipients and diluents that can be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose , Microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which are prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose, lactose, It is prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the non-aqueous solvent and suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of suppository bases include withexol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The term "administering" as used herein is meant to provide any desired composition of the invention to a subject in any suitable manner.

The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the drug form, the administration route and the period, and can be appropriately selected by those skilled in the art. For the desired effect, the thiazolone derivative of the present invention may be administered in an amount of 1 μg / kg to 1000 mg / kg per day. The composition may be administered once a day, or divided into several doses.

The pharmaceutical composition of the present invention may be administered to a subject in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.

The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the prevention or treatment of platelet aggregation inhibition or thrombotic diseases.

In the present invention, the term " health functional food " refers to a food having a biological control function such as prevention and improvement of disease, bio-defense, immunity, recovery after disease and aging inhibition.

The thiazolone derivative (PT1) of the present invention can be added to health functional foods for the purpose of inhibiting platelet aggregation or preventing or improving thrombotic diseases. When the thiazolone derivative (PT1) of the present invention is used as a food additive, the thiazolone derivative (PT1) may be directly added or used together with other food or food ingredients, and suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, the thiazolone derivative (PT1) of the present invention is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.

There is no particular limitation on the kind of the food. Examples of the foods to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, natural sweeteners such as dextrin and cyclodextrin, synthetic sweeteners such as saccharine and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 10 g, preferably about 0.01 to 0.1 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, A carbonating agent used in a carbonated beverage, and the like. In addition, the composition of the present invention may comprise flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, preferred embodiments and production examples are provided to facilitate understanding of the present invention. However, the following Examples and Preparation Examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the Examples and Production Examples.

Example . Anti-thrombosis  Verification of effect

To test the antithrombotic effect, rats were anesthetized with diethyl ether and blood was isolated via the aorta. Platelet aggregation was induced with thrombin after 20 minutes of treatment with thiazolone derivative (PT1) at various concentrations (25, 50, and 100 μM) after preparing platelets from isolated whole blood. The degree of platelet aggregation was measured using a 4-channel aggregometer (Chronolog Corp., Havertown, Pa.) According to a known method. The results are shown in Fig.

As shown in FIG. 1, the platelet aggregation was induced by the trimbin treatment, and when the thiazolone derivative (PT1) of the present invention was pretreated, an antithrombotic effect in which platelet aggregation was inhibited in a concentration-dependent manner was confirmed.

Further, the blood was pretreated with CC (compound C) or ara-A, which is known as a substance inhibiting the activity of the thiazolone derivative (PT1), for 15 minutes, and then the thiazolone derivative PT1 (1000 μM) Platelet aggregation was induced by thrombin. The results are shown in Fig.

Platelet aggregation was induced by thrombin treatment, and platelet aggregation was inhibited when the thiazolone derivative (PT1) was pretreated, and CC or ara-A, which is an inhibitor of the thiazolone derivative (PT1), was pretreated In one case, platelet aggregation was activated.

From the above experimental results, it was confirmed that the thiazolone derivative (PT1) of the present invention has an inhibitory effect on platelet aggregation and can be used as a composition for preventing platelet aggregation or for preventing or treating thrombotic diseases.

Hereinafter, examples of pharmaceutical composition and food composition containing the composition of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically described .

Formulation example  1. Preparation of pharmaceutical compositions

1-1. Sanje  Produce

20 mg thiazolone derivative (PT1)

Lactose 100 mg

Talc 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

1-2. Manufacture of tablets

Thiazolone derivative (PT1) 10 mg

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

1-3. Preparation of capsules

Thiazolone derivative (PT1) 10 mg

Crystalline cellulose 3 mg

Lactose 14.8 mg

Magnesium stearate 0.2 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

1-4. Injection preparation

Thiazolone derivative (PT1) 10 mg

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na ₂ HPO ₄ .2H ₂ O 26 mg

(2 ml) per 1 ampoule in accordance with the usual injection preparation method.

1-5. Liquid  Produce

20 mg thiazolone derivative (PT1)

10 g per isomer

5 g mannitol

Purified water quantity

Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.

Formulation example  2. Preparation of food composition

2-1. Manufacture of health food

100 mg of thiazolone derivative (PT1)

Vitamin mixture quantity

Vitamin A acetate 70 μg

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

0.15 mg of vitamin B2

Vitamin B6 0.5 mg

Vitamin B12 0.2 μg

Vitamin C 10 mg

Biotin 10 μg

Nicotinic acid amide 1.7 mg

Folic acid 50 μg

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

2-2. Health drink  Produce

100 mg of thiazolone derivative (PT1)

Vitamin C 15 g

Vitamin E (powder) 100 g

19.75 g of ferrous lactate

3.5 g of zinc oxide

Nicotinic acid amide 3.5 g

Vitamin A 0.2 g

Vitamin B1 0.25 g

Vitamin B2 0.3g

Water quantification

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 liter container, It is used in the production of the health beverage composition of the invention.

Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

Claims (5)

A pharmaceutical composition for inhibiting platelet aggregation comprising a thiazolone derivative represented by the following formula (1) as an active ingredient.
[Chemical Formula 1]

1. A food composition for inhibiting platelet aggregation comprising a thiazolone derivative represented by the following formula (1) as an active ingredient.
[Chemical Formula 1]

1. A pharmaceutical composition for preventing or treating thrombotic diseases, comprising a thiazolone derivative represented by the following formula (1) as an active ingredient.
[Chemical Formula 1]

4. The method of claim 3, wherein the thrombotic disease is selected from the group consisting of myocardial infarction, angina pectoris, thrombotic phlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, peripheral vascular thrombosis, deep vein thrombosis, arterial thrombosis, venous thrombosis, ischemic cerebral infarction, , Pulmonary hypertension, cerebral infarction, stroke, chronic arterial occlusion, postmenopausal syndrome, cerebral embolism, renal embolism, thromboembolism, pathologic symptoms after subarachnoid hemorrhage, thrombus formation upon percutaneous coronary angioplasty (PTCA) or stent insertion, Characterized in that it is at least one selected from the group consisting of post-restenosis, catheter thrombotic occlusion or reocclusion, acute coronary syndrome, TIA (transient ischemic attack or acute cerebrovascular syndrome) and heart failure. Composition. 1. A food composition for preventing or ameliorating a thrombotic disease, comprising a thiazolone derivative represented by the following formula (1) as an active ingredient.
[Chemical Formula 1]

Images